Suggesting a new combination of antiviral agents: Targeting the Herpes Simplex Virus.
Loading...
Date
2014-09
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Herpes simplex is a viral disease caused by herpes simplex virus type 1 and type 2.Several broad spectrum drugs
are available but most of the strains developed resistance against it. To overcome this problem, we are suggesting
a new combination drug for the treatment of herpes simplex. The main aim of the hypothesis is to formulate a
topical drug and an intravenously administered drug against herpes simplex virus. Chebulagic acid and
Punicalagin inhibit HSV-1 entry at non-cytotoxic doses in A549 human lung cells. sodium is important to curb
the proliferation and cell to cell spread of herpes simplex virus. TA205, an antitalin monoclonal antibody can be
microinjected in human fibroblasts. It causes allosteric inhibition on integrin binding to the talin protein FERM
domain. Sodium lauryl sulphate is a surfactant which enhances intra epidermal drug delivery without increasing
transdermal delivery. Amphipathic DNA polymers work against HIV binding and entry. Candidate topical
microbicides are efficient against viral entry and cell to cell spread by binding HSV glycoprotein B. Thus, a
combination of the above mentioned drugs can be used to prevent HSV binding, cell to cell spread and infection.
Description
Keywords
HSV, aciclovir, intergin, chebulagic acid, monoclonal antibody
Citation
Devi Subathra C, Chawla Taneesha, Abbasi Nida Itrat, Upadhyay Nupoor Neha, Mohanasrinivasan V. Suggesting a new combination of antiviral agents: Targeting the Herpes Simplex Virus. Journal of Applied Pharmaceutical Science. 2014 Sept; 4(9): 114-119.